Degludec fares better than glargine in glucose control

04/23/2012 | Medical News Today

Type 2 diabetes patients who took insulin degludec showed lower rates of overall hypoglycemic episodes per year than their counterparts who received insulin glargine, according to two Phase III studies in The Lancet. Researchers also found that patients with type 1 or type 2 diabetes who were on degludec treatment had a 25% reduction in nocturnal hypoglycemia rates compared with those who took glargine.

View Full Article in:

Medical News Today

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Director, Compliance - Health Plan Privacy & Security
Kaiser Permanente
Oakland, CA
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ